Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa

Yixin Kang, Lu Xie, Jiyong Yang, Junchang Cui

Frontiers in Cellular and Infection Microbiology · 2023 · 15 citations · 20 references

DOIFull text

Open access

Abstract

AZA has been considered as an option for the treatment of infections caused by XDR/PDR <i>P. aeruginosa</i> producing IMP-45, VIM-1, or VIM-2. OTAT with sufficient pharmacodynamic exposure may be an optimal treatment option for XDR/PDR <i>P. aeruginosa</i> with a high-level MIC of CZA/AZA.

References

20